ERBB2 and neoplasm: Currently, the usefulness of such a pretargeted strategy for a rapidly internalizing antigen, such as HER2, is limited; antibody-mediated internalization of HER2 reduces the availability of the antibody and its associated clickable sites on the tumor for the incoming radioligand, which can bear an imaging or therapeutic radionuclide.